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Abstract
Background: Nck1 and Nck2 adaptor proteins are involved in signaling pathways mediating proliferation,
cytoskeleton organization and integrated stress response. Overexpression of Nck1 in fibroblasts has been shown to
be oncogenic. Through the years this concept has been challenged and the consensus is now that overexpression
of either Nck cooperates with strong oncogenes to transform cells. Therefore, variations in Nck expression levels in
transformed cells could endorse cancer progression.
Methods: Expression of Nck1 and Nck2 proteins in various cancer cell lines at different stages of progression were
analyzed by western blots. We created human primary melanoma cell lines overexpressing GFP-Nck2 and
investigated their ability to proliferate along with metastatic characteristics such as migration and invasion. By
western blot analysis, we compared levels of proteins phosphorylated on tyrosine as well as cadherins and
integrins in human melanoma cells overexpressing or not Nck2. Finally, in mice we assessed tumor growth rate of
human melanoma cells expressing increasing levels of Nck2.
Results: We found that expression of Nck2 is consistently increased in various metastatic cancer cell lines
compared with primary counterparts. Particularly, we observed significant higher levels of Nck2 protein and mRNA,
as opposed to no change in Nck1, in human metastatic melanoma cell lines compared with non-metastatic
melanoma and normal melanocytes. We demonstrated the involvement of Nck2 in proliferation, migration and
invasion in human melanoma cells. Moreover, we discovered that Nck2 overexpression in human primary
melanoma cells correlates with higher levels of proteins phosphorylated on tyrosine residues, assembly of Nck2-
dependent pY-proteins-containing molecular complexes and downregulation of cadherins and integrins.
Importantly, we uncovered that injection of Nck2-overexpressing human primary melanoma cells into mice
increases melanoma-derived tumor growth rate.
Conclusions: Collectively, our data indicate that Nck2 effectively influences human melanoma phenotype
progression. At the molecular level, we propose that Nck2 in human primary melanoma promotes the formation of
molecular complexes regulating proliferation and actin cytoskeleton dynamics by modulating kinases or
phosphatases activities that results in increased levels of proteins phosphorylated on tyrosine residues. This study
provides new insights regarding cancer progression that could impact on the therapeutic strategies targeting
cancer.
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Melanoma skin cancer is one of the most devastating
types of cancer, extremely aggressive with high meta-
static potential. Melanoma metastasis to distant organs
is the primary cause of human cancer-related deaths.
Worldwide, the incidence of cutaneous malignant mela-
noma is increasing faster than any other type of cancer.
Cutaneous melanoma originates from pigment-produ-
cing melanocytes localized at the epidermal-dermal
junction in human skin and develops through different
steps [1]. Among various hypotheses, it is proposed that
these involve radial (RGP) and vertical (VGP) aberrant
growth phases of preexisting nevi or at new site. Then
to metastasize at distant sites, melanoma detach from a
primary lesion, acquire motility and proteolytic activities
to reach lymphatic and blood circulation and undergo
growth to distinct organs, all this according to stepwise
molecular changes involving defined genetic events
[2,3]. However, the exact mechanisms underlying this
devastating process are complex and somehow still
poorly understood. From a molecular point of view,
oncogenic activation of the mitogen-activated protein
kinase (MAPK) pathway, due to somatic mutations in
B-RAF (V600E), is frequently observed in melanoma
(70%) [4].
In mammals, the family of Nck (non-catalytic region
of tyrosine kinase) proteins is represented by two highly
conserved members, Nck1 and Nck2, composed of three
N-terminal SH3 (Src homology 3) domains followed by
a unique C-terminal SH2 (Src homology 2) domain and
devoid of any catalytic activity [5,6]. Like other SH2/
SH3 domain-containing proteins, Nck1 and Nck2
behave as adaptor proteins by physically coupling acti-
vated membrane receptors to specific downstream effec-
tors [7]. In mice, individual Nck knockout resulted in no
phenotype, confirming redundancy of Nck proteins,
while early embryonic lethality of the double Nck knock-
out mice revealed their crucial role in embryonic devel-
opment [8]. However, regardless that Nck1 and Nck2
share high amino acid identity, and common cellular
functions and binding partners, increasing evidence sup-
port specific roles and proteins interactions, as well as
tissue expression patterns for these adaptors [7,9-15].
Previous studies have reported that overexpression of
Nck1 in fibroblasts induces cellular transformation and
that these cells form tumors in mice [16,17]. Further-
more, either Nck has been shown to cooperate with
potent oncogenes (v-Abl and Ras) to transform cells,
influence cell morphology and anchorage-independent
growth [6]. Although, these studies strongly suggest a
role for Nck in cancer development, the mechanism by
which Nck oncogenic potential is achieved still remains
to be established.
Originally the Nck1 cDNA was isolated from a human
melanoma cDNA expression library using a monoclonal
antibody produced against the human melanoma-asso-
ciated antigen [5], which has no similarity with Nck1.
This suggests that the Nck1 mRNA might be abundant
in human melanoma. Most recently, the Nck2 gene was
found as being overexpressed in human metastatic mel-
anoma compared with non-metastatic melanoma lesions
[18]. In agreement, the cancer microarray database
Oncomine (https://www.oncomine.org/) reports Nck2 as
a gene upregulated in several human cancer cell lines,
including human melanoma. Therefore, the concept that
deregulated expression of Nck adaptor proteins could
contribute to promote melanoma development and/or
progression deserves further investigation. In the present
study, using human melanoma cell lines harboring the
activating B-RAF (V600E) mutation, that are well
defined for stage of cancer progression [19,20], we
demonstrate that Nck2 protein and mRNA levels are
increased in human metastatic melanoma cells com-
pared with human primary melanoma cells that rarely
metastasis. We show that Nck2 promotes cell prolifera-
tion, migration and invasion in human melanoma cells.
In addition, using an in vivo xenograft model, we pro-
vide evidence that increased Nck2 expression in human
primary melanoma cells promotes melanoma-derived
tumor growth rate. Collectively, our findings indicate
that Nck2 plays a role in human melanoma progression.
Methods
Cell lines
T h eW i s t a rm e l a n o m ac e l l lines (WM278, WM1232,
WM115, 1205Lu, WM164, WM1617 and 451Lu) were
obtained from Dr Meenhard Herlyn (PA, USA). Human
Epidermal Melanocytes (HEM) cell line was purchased
from Cell Applications Inc. Murine colon carcinoma cell
(CT26, CT36 and CT51) were obtained from Dr. Nicole
Beauchemin (McGill University, Montreal, QC). Breast
cancer cell lines (MCF10, MCF7, T47D, MDA-MB-231)
were kindly provided by Dr. Morag Park (McGill Uni-
versity, Montreal, Qc).
Cell culture
Unless specified, all chemicals used in this study are
from regular commercial sources. Cells were maintained
at 37°C in 5% CO2-95%O2 atmosphere. HEK293, colon
and breast cancer cell lines were grown in DMEM (Dul-
becco’s modified Eagle’s medium) containing 10% FBS
and supplemented with 100 Units/ml of penicillin, 100
μg/ml of streptomycin and 0.25 μg/ml of Amphotericin
B. Melanoma cell lines were grown in RPMI 1640 sup-
plemented with 2 mg/ml NaHCO3 and 0.3 mg/ml gluta-
mine. MCF10 cells were grown in DMEM containing
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dermal growth factor (mEGF, Collaborative Biomedical
Products), 10 μg/ml of insulin and 0.1 μg/ml of cholera
toxin. To induce MCF10 cell differentiation, cells were
grown in media in absence of mEGF but supplemented
with 0.5 μg/ml of hydrocortisone for two days. HEM
(human epidermal melanocyte) cells were grown in
HEM media (Cell Applications Inc.) and cultured
according to the manufacturer’s instructions.
To analyze phospho-tyrosine proteins, cells were
exposed to protein phosphotyrosine phosphatase inhibi-
tor (pervanadate (Na3VO4)o rb p V P h e n ,1 0 0μM, 15
min at 37°C) prior to be harvested and total cell lysates
processed for anti-phosphotyrosine western blot as
reported below. Alternatively, total cell lysates (2 mg
protein) were incubated with indicated antibodies (4 μg)
for 2 hours at 4°C and 40 μl of 50% slurry solution of
Protein-A immobilized on Sepharose beads (Santa Cruz
Biotech.) were added for an additional 2 hours of incu-
bation at 4°C. Immunoprecipitated samples were washed
3X with lysis buffer before to be finally recovered in
Laemmli buffer and processed for anti-phosphotyrosine
western blot as reposted below.
Antibodies
Nck polyclonal antibodies were raised by immunizing
rabbits with GST-Nck fusion proteins as antigens.
Crude serum samples were Protein-A-purified (Pro-
Chem, MA) and further tested for Nck specificity as
described below. A pan-Nck antibody (1793), which
recognizes both Nck isoforms was raised against resi-
dues 1-251 containing the three SH3 domains of human
Nck1 as previously reported [21]. Nck1 antibody (2383)
and Nck2 antibody (3313) were raised against isoform
specific amino acid sequence in between the last SH3
and the SH2 domain of each Nck as reported earlier
[15]. Other antibodies used are: CrkII (C-18), Integrin
b3 (H-96), phospho-tyrosine (clone PY99), HA (Y-11)
and GFP (B-2) from Santa Cruz Biotech. Antibodies
against Integrin b1 (anti-CD29, clone 18), E-Cadherin
(clone 34) and N-Cadherin (clone 32) were purchased
from BD (ON, Canada). Antibodies to detect vinculin
(clone h-VIN-1) and Tubulin (TUB2.1) were from
Sigma-Aldrich, USA. Secondary antibodies coupled to
HRP were from Bio-Rad Inc. Rhodamine-coupled to
mouse anti-IgG was bought at Jackson ImmunoResearch
Inc. Phalloidin-coupled to AlexaFluor
®555 and 488 were
purchased from Molecular Probes (Invitrogen, CA,
USA)
Cell lysis and western blots
Cell lysates were prepared in lysis buffer (50 mM
HEPES pH 7.4, 150 mM NaCl, 10% Glycerol, 1% Triton
X-100, 1.5 mM MgCl2,1m ME G T A ,1 0m MS o d i u m
Pyrophosphate, 100 mM Sodium Fluoride, supplemen-
ted with the protease inhibitors Aprotinin and Leupep-
tin at 1 μg/ml and PMSF at 1 mM. Lysates normalized
for protein content (Bradford protein assay, Bio-Rad)
were prepared in Laemmli buffer, heated, subjected to
SDS-PAGE on 10% acrylamide gels and transferred onto
nitrocellulose membranes. For western blot analyses,
membranes were blocked in TBS (Tris-buffered saline)
containing 10% dry milk and 0.1% Tween-20, and then
incubated overnight at 4°C with indicated primary anti-
bodies appropriately diluted in the blocking solution.
For pY western blot, blocking and primary antibody
solution was TBS containing 5% bovine serum albumin
(BSA, Sigma) and 0.1% Tween-20. Next morning, the
membranes were washed twice with TBS for 5 minutes
followed by two 5 minutes washes using TBS-T (TBS-
0.1% Tween-20) and two 5 minutes washes with TBS.
The membranes were then incubated with secondary
antibody appropriately diluted in milk-blocking solution
for 1 hour and washed as above. Finally, signal was
detected using ECL Plus Western Blotting Detection
System (GE Healthcare, UK) and XR film exposure.
RNA isolation and RT-PCR
Total RNA was isolated from melanoma cells using the
TRIZOL (Invitrogen) according to the manufacturer’s
protocol. Briefly, cells from 100-mm dishes (1 × 10
6
cells) were suspended in 7.8 ml of TRIZOL. The aqu-
eous and organic phases were separated after addition of
chloroform. Precipitated RNA by isopropyl alcohol addi-
tion was washed in 70% ethanol and dissolved in
RNase-free water. RNA concentration and purity
(OD260/280) was measured using an Ultrospec 2100 Pro
UV/visible Spectrophotometer (Fisher Scientific, ON).
First-strand cDNA synthesis was generated by reverse
transcriptase reaction in a final volume of 50 μl. For
this, 2.0 μg of total RNA were mixed in a total reaction
volume of 20 μl of RNAse free water containing 1 μM
Oligo d(T)20 for Nck amplifications or 6 μgo fR a n d o m
Primers for 18S amplification. The reactions were incu-
bated at 65°C for 5 min and quenched on ice. Then, the
RT reaction was assembled by adding 10 μlo ft h e5 X
1
st strand buffer (Invitrogen), 5 μlo f0 . 1MD T T( I n v i -
trogen), 2.5 μl of RNase Inhibitor (40 U/μl) (Invitrogen),
2.5 μl of 10 mM dNTPs, 5 μl of 50 mM MgSO4 and 2.5
μlo fS u p e r s c r i p tI I I( 2 0 0U / μl) (Invitrogen). Samples
were incubated at 37°C for 50 min and deactivated at
70°C for 15 min. PCR amplification was performed
using 0.5 μl of cDNA template in a final volume of 50
μl containing 5 μl of 10X PCR Enhancer buffer (Invitro-
gen), 1.5 mM MgCl2, 0.2 mM dNTPs, 50 pM of specific
forward and reverse primers, 10 μl of Amplification buf-
fer (Invitrogen) and 1 U of Taq DNA polymerase (Invi-
trogen) and DEPC water. Primers used were: Nck1
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reverse 5’-ACACTTGCCCAGTATTTAGG-3’, Nck2 for-
ward 5’-CGAGTACCCCGCCAATGG-3’ and Nck2
reverse 5’-CCCGTCACTGAGGACCACC-3’. Reactions
were carried out on PTC-100 Programmable Thermal
Controller (MJ Research Inc.) according to the following
program conditions: initial denaturation at 94°C for 1
min, followed by 1 min at 94°C, 30 seconds of annealing
(47°C for Nck 1, 53°C for Nck 2 and 55°C for 18S) and
1 min at 72°C. The final elongation step was 10 minutes
at 72°C and the samples were kept at 4°C until analysis.
PCR products were separated on a 1% agarose gels and
imaged using an NIH Image J 1.30 system. Fifteen, 20,
25 and 30 cycles of PCR amplification products were
analyzed to confirm that the amplification was in the
linear range for each gene. Ratios of Nck1 and Nck2
over 18S were calculated from similar assays performed
in triplicate and repeated three times.
Cell transfection
Human HA-tagged Nck2 cDNA generously provided
by Dr. Wei Li (University of Southern California, LA,
CA) was subcloned into the retroviral vector pLXSN
(Clonetech Laboratories Inc., CA, USA) and the viral
particles produced using the GP2-293 cell line accord-
ing to the manufacturers’ instructions. Human Nck2
cDNA was also subcloned into the pEGFP-C1 plasmid
(BD, NJ, USA). To establish stable clones of human
WM278 primary melanoma overexpressing GFP or
GFP-Nck2, cells plated in 100-mm dishes (1 × 10
6
cells) were transiently transfected with 10 μgo fp l a s -
mid DNA (pEGFP or pEGFP-Nck2) using calcium
phosphate and following selection with neomycin,
clones were isolated, amplified and analyzed for GFP
or GFP-Nck2 by western blot. 451Lu cells plated at
40-60% confluence were transfected with either 100
nM Nck2 or control siRNA 13379 (Ambion, Austin,
TX) using Lipofectamine Plus reagent according to the
manufacturer’s protocol and analyzed for protein
expression after 24 or 48 h.
Proliferation assays
Briefly, cells (4 × 10
3) were seeded in 96-well plates and
24, 48, 72 or 96 h after, cells were fixed by adding glu-
taraldehyde (20 min, final concentration 1%). Then,
fixed cells were washed twice with deionised water and
stained with Crystal Violet (20 min, 0.4% in 10% etha-
nol, Sigma). The excess of Crystal Violet was removed
by washing the cells three times with water and finally,
incorporated Crystal Violet was dissolved in 10% acetic
acid and read at 570 nm using a spectrophotometer
(Beckman Coulter). Wells without cells, but containing
medium were used as blank value that was subtracted
from all values. Data were expresses a raw OD at 570
nm or as ratio of OD at specific time point over initial
OD at day 1.
Wound healing assays
Cell migration was assessed in classical wound healing
assays. Confluent monolayer cells in a 6-well plate were
wounded using a plastic pipette tip (P200) and rinsed
with PBS before to add back culture medium. The bot-
toms of the wells were marked to indicate where the
initial pictures of the wound area were taken. After 8 h
incubation at 37°C, pictures (10X) of the same areas
were recorded using an Axiovert 200 M microscope
(Zeiss) equipped with a CoolSnap™ES camera (Photo-
metric
®, Roper Scientific) and closure of the wound
evaluated using Metamorph
® (V6.3, Molecular Devices
Corp.).
Cell invasion assays using Transwells
Melanoma cells (1 × 10
5) resuspended in 10% serum
containing medium were added to the top chamber of a
Transwell (8 μm, DD Biosciences, NJ, USA) pre-coated
with matrigel™ (BD Biosciences, NJ, USA) diluted in
ice-cold PBS (175 μg/ml) at a total of 35 μgp e rw e l l
and allowed to migrate for 24 h. To evaluate the
amount of cells that had invaded through each trans-
well, excess of media was discarded and the transwells
were washed once with PBS and then placed in trypsin
solution (0.025%) to release the invaded cells underside
of the transwells and in the bottom chamber. Total
invaded cells were estimated using Calcein AM (BD
Biosciences, NJ, USA) as recommended by the manufac-
turer. Data were normalized according to the respective
total amount of cells for each line plated at the same
time in adjacent wells devoid of transwells to take into
account variations in cell number between cell lines.
Spheroid formation assays
Spheroid formation and culture in 3D were performed
according to the hanging drop method [22]. Briefly, 2 ×
10
4 cells in 20 μl of culture medium were suspended on
the lid of tissue culture dishes containing 10 ml of cul-
ture medium for 48 h to form spheroids. Then spher-
oids were transferred in culture dishes containing
culture medium and on 2% agar (Agar Select, Invitro-
gen, CA, USA) at the bottom. After 72 h of growth in
suspension, individual spheroid has been transferred in
4-well plate containing 80% collagen type IV (PureCol
®,
Advanced BioMatrix) in RPMI without FBS. Following
30 min at 37°C to allow collagen polymerization, 500 μl
of RPMI containing 10% FBS was added to each well.
Images were recorded initially and at 12-24 hr intervals
as reported above for wound healing assays. Spheroid
invasion was determined qualitatively as either positive
or negative comparing sequential images.
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Cells were plated at 3 × 10
4 cells/well on glass coverslips
pre-coated or not with various extracellular matrices
and incubated in culture medium for 24 h. All steps
were carried at room temperature and coverslips were
rinsed with PBS between each step. Cells were fixed in
freshly prepared 3.7% formaldehyde for 10 min, permea-
bilized in 0.2% Triton-X-100 for 5 min and blocked in
0.1% BSA for 30 min. For vinculin staining, cells were
incubated with primary monoclonal anti-vinculin anti-
body (1:400) for 1 h and with a mixture of secondary
tetramethylrhodamine isothiocyanate-conjugated phalloi-
din-conjugated goat mouse antibody (TRITC-GAM,
Sigma) for 30 min. Actin staining was performed by
incubating the coverslips for 30 min with Phalloidin-
AlexaFluor
®555. Coverslips were mounted by inverting
them on glass slides using Prolong anti-fade mounting
media (Molecular Probes). Coverslips were examined on
a Zeiss Axiovert 200 M microscope (Zeiss) using 40X or
oil immersion 63× objective lens. Fluorescent images
were captured using a CoolSnap™ES camera (Photo-
metric
®, Roper Scientific) and analyzed using Meta-
morph
® (V6.3, Molecular Devices Corp.).
Tumor growth in vivo
WM278 primary melanoma cells either parental, overex-
pressing GFP (C2) or GFP-Nck2 at low (N7) or high
(N14) levels were grown in RPMI medium supplemen-
ted with 10% FBS to 80% confluency. Cells (5 × 10
6)
resuspended in 500 μla t5 0 %M a t r i g e l ™ were injected
subcutaneously in the right flank of 6-week-old CD-1
Nude mice (Charles River, Qc, Canada) (n = 5 for each
group). Tumors development was followed for 20 weeks.
Tumor size was measured every week with calipers to
assess tumor volume ([πlength × width
2]/6). Mice were
housed in McGill University Animal facilities at the
Genome building. Mice experiments were conducted
under a McGill University-approved animal use protocol
(Dr. P.M. Siegel) in accordance with guidelines estab-
lished by the Canadian Council on Animal Care.
Data analysis and statistics
Densitometry analysis results are expressed as means ±
S.E.M. Student’s t test was used to evaluate the statisti-
cal significance of the results. A p ≤value 0.05 is
assumed to be significant.
Results
Nck2 protein and mRNA levels are increased in human
metastatic melanoma cell lines
To investigate the potential involvement of Nck proteins
in human melanoma development and progression, we
first analyzed total Nck protein levels in human mela-
noma cell lines at different stages of cancer progression
and compared with normal human melanocytes. The
human melanoma cell lines used in this study were pro-
vided by the laboratory of Dr. Meenhard Herlyn at the
Wistar Institute (PA, USA) and already used in vivo for
tumorigenicity and experimental metastasis [23,24].
Mainly, these include the WM278, a melanoma cell line
derived from a human primary tumor in vertical growth
phase that rarely metastasis; WM1617, a WM278 sister
melanoma cell line derived from lymph nodes metastasis
in the same patient few years later; 451Lu, a melanoma
cell line isolated from lung metastasis in mice injected
with the WM164 cell line, which is a human melanoma
cell line isolated from lymph nodes metastasis similar to
WM1617, but from a different patient.
From western blots performed using a rabbit polyclo-
nal antibody that equally recognizes both Nck isotypes
(Pan-Nck, Additional file 1) [21], we observed higher
levels of Nck proteins in highly metastatic melanoma
(WM164, 451Lu, 1205Lu and WM1232) compared with
weakly metastatic primary melanoma (WM115 and
WM278) and normal melanocyte (FW2294) cell lines
(Figure 1A). Further analyses using in-house generated
Nck isoforms specific antibodies (Additional file 1) [15]
revealed that increased expression of Nck in metastatic
melanoma cells is mainly due to drastic higher expres-
sion levels of Nck2 (Figure 1B, compare WM164 and
451Lu with WM278). Additional comparison of highly
metastatic (WM1617) and weakly metastatic (WM278)
human melanoma cell lines isolated from the same
patient (Figure 1B), further confirmed increased expres-
sion of Nck2 in human metastatic melanoma. Interest-
ingly, Nck1 protein levels normalized according to actin
or tubulin loading control were comparable among the
human melanoma cell lines investigated (Figure 1B and
Additional file 2). In addition, we also found no change
in expression levels of other SH2/SH3 domain-contain-
ing signaling proteins, such as PLC-g1, p85 of PI3K,
Grb2 and Crk, as normalized for actin or tubulin load-
ing control (Additional file 2 and data not shown). Alto-
gether, these results suggest a specific role for Nck2 in
human melanoma progression.
To assess whether increased expression of Nck2 protein
levels in human metastatic melanoma cells correlates
with upregulated transcription of Nck2 gene, we com-
pared Nck1 and Nck2 mRNA levels in three human
melanoma cell lines at different stages of progression
and in human primary melanocytes (HEM) by perform-
ing RT-PCR using Nck isoforms specific primers. In the
linear range of PCR amplification, no significant change
in Nck1 mRNA levels was detected in all human mela-
noma cell lines and compared with HEM (Figure 2A).
In contrast, we observed a strong increase in Nck2
mRNA levels in all human melanoma cell lines com-
pared with HEM. In addition, compared with primary
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lines (WM164 and 451LU) showed significant increased
Nck2 mRNA levels (Figure 2B). Altogether, our results
reveal that Nck2 protein and mRNA levels are signifi-
cantly increased in different human metastatic mela-
noma cells compared with human weakly metastatic
primary melanoma and melanocyte cells, suggesting
Nck2 as a biological marker of human melanoma metas-
tasis that could contribute to melanoma progression.
Nck2 promotes human melanoma cell proliferation
To demonstrate a role for Nck2 in melanoma progres-
sion, we first determined whether Nck2 regulates cell
proliferation in WM278 human primary melanoma
cells, which endogenously express low levels of Nck2
protein and rarely metastasis compared with its meta-
static counterpart WM1617 melanoma cells. For this,
we created WM278 cell lines stably overexpressing
increasing levels of GFP-Nck2 (N15 < N7 < N14) or
GFP as control (C2) (Figure 3A). Using these WM278
stable cell lines, we found that overexpressing high
levels of Nck2 significantly enhanced cell proliferation
(Figure 3B, left panel, compare clone N14 with C2). It is
interesting to note though that the effect of Nck2 on
WM278 primary melanoma cells proliferation seems to
parallel the levels of Nck2 overexpressed (Figure 3A and
3 B ,c o m p a r e dN 1 5 ,N 7a n dN 1 4 ) .I na g r e e m e n t ,t h e
WM1617 human metastatic melanoma cells that endo-
genously express higher levels of Nck2 compared with
human primary melanoma cells, also show higher prolif-
erative abilities than its paired WM278 primary mela-
noma cells that rarely metastasis (Figure 3C). As
expected, we found no change in the protein levels of
Nck1 or CrkII, a SH2-SH3 domain-containing adaptor
p r o t e i np r e v i o u s l yi d e n t i f ya sa no n c o g e n e[ 2 5 ]a n d
recently reported to regulate sarcoma cell proliferation
[26] (Figure 3C).
To confirm a role for Nck2 in melanoma cell prolif-
eration, we assessed whether siRNA-mediated downre-
gulation of Nck2 in human metastatic melanoma cells
affects cell proliferation. A ss h o w ni nF i g u r e4 A ,N c k 2
siRNA transfection of 451Lu metastatic melanoma cells
resulted in decreased Nck2 protein and mRNA levels,
while Nck1 protein and mRNA levels were not altered.
More importantly, we found that cell proliferation was
significantly decreased in Nck2 depleted metastatic mel-
anoma cells compared with control siRNA treated cells
(Figure 4B). To rule out that this effect was due to
increased cell death in Nck2 depleted melanoma cells, 2
days post transfection we evaluated the percentage of
cells with nuclei stained by Trypan Blue and observed
no difference between metastatic melanoma cells trans-
fected with control (8.7% ± 2.5) and Nck2 (7.7% ± 1.7)
siRNA. Altogether, these results indicate that Nck2
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Figure 1 Nck expression in human melanoma cell lines at
different stages of cancer progression. Equivalent amount of
total proteins from human primary and metastatic melanoma cell
lysates (30 μg) were subjected to western blot analysis using
indicated antibodies. (A) Pan-Nck antibodies recognize Nck1 and
Nck2. eIF2a was used as loading control. (B) Nck1 and Nck2 are
specific Nck isotypes antibodies (Additional file 1) and b-actin or
tubulin was detected as loading controls. Quantification of Nck1
and Nck2 signals, evaluated in the linear range of detection by
densitometry, are reported below the blots. Human Melanoma Cell
Lines Characteristics: FW2294: normal melanocyte; WM115: poorly
metastatic primary melanoma in vertical growth phase and with
round morphology; WM164: elongated metastatic melanoma
isolated from lymph nodes; WM278: poorly metastatic primary
melanoma in vertical growth phase and with mixed morphology;
WM1617: elongated metastatic melanoma derived from lymph
nodes, sister match of WM278; 451Lu: elongated metastatic
melanoma selected in lungs of mice injected with WM164 cells;
1205Lu: round metastatic melanoma selected in mice; WM1232:
round metastatic melanoma.
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melanoma cells.
Nck2 modulates migration and invasion of human
melanoma cells
Cancer progression involves that transformed cells must
acquire motility and invasive activities. Therefore, we
next determined whether Nck2 was critical to melanoma
cell migration and invasion. We compared migration of
WM278 primary melanoma cells overexpressing GFP
(C2) or increasing levels of GFP-Nck2 (N15 < N7 <
N14) in wound healing assays. As shown in Figure 5,
increasing levels of GFP-Nck2 in WM278 melanoma
cells promoted migration and this was significant in cell
line N14, which expresses higher levels of Nck2 proteins
compared with N5 and N7 cell lines (Figure 3A). To
exclude that a clonal effect is responsible of increased
migration of WM278 melanoma cells overexpressing
GFP-Nck2, we transiently overexpressed HA-Nck2 in
WM278 primary melanoma cells using retroviral
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Figure 2 Nck1 and Nck2 mRNA expression in human melanocytes and melanoma cells. (A) RT-PCR amplification performed on isolated
RNA from human melanocyte and melanoma cells using specific primers for human Nck1, Nck2 and 18S. Shown are PCR products after 20 and
25 cycles of amplification. HEM: human normal melanocytes; WM278: human primary melanoma that rarely metastasis; WM164: human
melanoma isolated from metastasis in lymph nodes; 451Lu: lung melanoma metastasis of WM164 injected in mice. 18S is used as control. (B)
Ratios of Nck1 and Nck2 mRNA over 18S were calculated from quantification by densitometry of PCR amplification products in the linear range.
Asterisk: p ≤ 0.001 compared to HEM, black triangle: p ≤ 0.001 compared to WM278.
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Figure 3 Effect of Nck2 on human primary melanoma cell proliferation. (A) Total cell lysates from stable WM278 human primary melanoma
cells overexpressing GFP (C2) or increasing levels of GFP-Nck2 (N15 < N7 < N14) were subjected to western blot analysis using GFP or Nck2
specific antibodies. Cell proliferation of (B) WM278 cells stably overexpressing GFP (C2) or GFP-Nck2 (N15, N7 and N14), as well as (C) parental
primary (WM278) and metastatic (WM1617) melanoma cells was determined by quantification of Crystal Violet incorporation each day during 4
days in culture. Results are shown as the ratio of the mean of cell density over day 1 ± SD (n = 4). * p < 0.02, ** p < 0.006 and ***p ≤
0.0001compared with C2 (B) or parental WM278 cells (C) using Student’s t-test. (D) Nck1 and CrkII expression was evaluated using total cell
lysates (30 μg protein) prepared from WM278 cells stably overexpressing GFP (C2) or GFP-Nck2 (N15, N7, and N14). b-tubulin was used as
loading control.
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Page 8 of 19infection (Additional file 3). In this context, we still
observed a significant increase in migration of WM278
human primary melanoma cells overexpressing HA-
Nck2 compared to control infected WM278 melanoma
cells in wound healing assays. It is interesting to note
though that the effect of Nck2 on migration was already
observed 8 hours after wounding, suggesting that cell
proliferation is not involved.
To determine whether overexpression of Nck2 in pri-
mary melanoma cells promotes invasion in a tumor-like
context, we evaluated migration of melanoma cells at
the edge of multicellular spheroids embedded into a col-
lagen type I matrix (Figure 6A). As expected, spheroids
of human primary melanoma cells overexpressing or not
G F P( W M 2 7 8 ,C 2 )g r e wa sc o m p a c tu n i t sd e v o i do f
cells migrating outward after 48 h in culture. In con-
trast, WM1617 human metastatic melanoma cells after
48 h in culture formed open-wave fragile spheroids with
cells in periphery sending long projections invading the
surrounding collagen. These observations are in agree-
ment with the established invasive phenotype of
WM1617 melanoma cells. Interestingly, WM278 human
primary melanoma cells overexpressing GFP-Nck2
(N14) apparently did not show similar extensions from
spheroid border cells, but form less compact spheroids
than WM278-GFP with individual cells that detached
form the mother spheroid after 48 h of culture into col-
lagen gel. This observation reveals that overexpression
of Nck2 in primary melanoma cells may contribute to
invasiveness by promoting cell detachment and migra-
tion from primary melanoma lesion in vivo. In agree-
ment, we found that Nck2 overexpression significantly
promoted primary melanoma cells invasion through
Matrigel™ matrix in transwells assays (Figure 6B). Alto-
gether, these results suggest that Nck2 promotes cell
migration and invasion in human melanoma cells.
Nck2 modulates focal adhesions in human melanoma
cells
Because Nck adaptor proteins play an important role in
regulating actin cytoskeleton reorganization, we then
compared actin staining in WM278 human primary
melanoma cells expressing either GFP (C2) or increasing
levels of GFP-Nck2 (N15 < N7 < N14) (Figure 7A).
Regardless of Nck2 expression levels, we found no
apparent change in actin staining in these cells. This
suggests that overexpression of Nck2 has no major
effect on actin polymerization and organization, as well
as on overall cell morphology in human primary mela-
noma. In contrast, vinculin staining, which shows that
GFP-Nck2 colocalizes with vinculin at focal adhesions
(Figure 7B), revealed significant reduced number of
focal adhesions in human primary melanoma cells over-
expressing Nck2 (N14) compared with control mela-
noma cells (C2) (Figure 7C). Therefore, these data
suggest that increased expression of Nck2 in human pri-
mary melanoma cells might facilitate melanoma migra-
tion by decreasing focal adhesions.
Nck2 promotes phosphorylation of proteins on tyrosine
and downregulation of cell surface adhesion proteins in
human primary melanoma cells
Protein tyrosine phosphorylation is a critical mechan-
ism regulating focal adhesion dynamics [27,28]. Sub-
stantial evidence support a role for protein tyrosine
kinases in focal adhesions assembly/disassembly toward
the formation of invasive adhesion structures called
invadopodia during cancer progression [29-33]. To
investigate the mechanism by which Nck2 overexpres-
sion impinges on the phenotype of primary melanoma
cells, we compared the levels of tyrosine phosphory-
lated proteins between human melanoma cells
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Figure 4 Effect of Nck2 on human metastatic melanoma cell
proliferation. (A) Total cell lysates (30 μg protein) prepared from
451Lu human melanoma cells transfected with control or specific
Nck2 siRNA were subjected to western blot analysis using specific
antibodies that recognize Nck1 or Nck2 (left panel). RT-PCR was
performed to determine Nck1 and Nck2 mRNA levels using total
RNA and specific primers for human Nck1 and Nck2. 18S was used
as control (right panel). (B) 451Lu human melanoma cells
transfected with control or Nck2 siRNA were followed for
proliferation 1 and 2 days after siRNA transfection. Results represent
cell density corresponding to the mean of Crystal Violet
incorporation ± SD from one experiment performed in triplicate. * p
< 0.05 vs control siRNA using Student’s t-test. Similar results were
found in three independent experiments.
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Page 9 of 19expressing different levels of Nck2 protein. To evaluate
protein tyrosine phosphorylation, we exposed mela-
noma cells to pervanadate, a potent protein tyrosine
phosphatase inhibitor [34-36] that allows tyrosine
phosphorylated proteins to accumulate before harvest-
ing the cells and performing immunoprecipitation. In
these conditions, as observed in human metastatic
(WM1617, WM164) compared with (WM278) mela-
noma cells (Figure 8A), WM278 cells overexpressing
GFP-Nck2 presented increasing levels of proteins
phosphorylated on tyrosine residues than WM278 con-
trol cells overexpressing GFP (Figure 8A). In addition,
we found that tyrosine phosphorylated proteins coim-
munoprecipitated with Nck2 (Nck2 IP) or total Nck
(pan-Nck IP) were more abundant in human meta-
static melanoma WM1617 cells compared with the
counterpart WM278 primary melanoma cells (Figure
8B). We discovered also that like the metastatic
WM1617 melanoma cells, the WM278 primary
melanoma cells overexpressing high levels GFP-Nck2
(N14) displayed low levels of Integrin b1a n db3, as
w e l la sE -a n dN - C a d h e r i ni nT r i t o nX - 1 0 0s o l u b l e
extracts compared either with parental WM278 cells,
WM278 cells overexpressing GFP (C2) or low levels of
GFP-Nck2 (N7) (Figure 9). Collectively, these results
reveal that increased expression of Nck2 in human pri-
mary melanoma cells promotes phosphorylation of
proteins on tyrosine, concomitant with the assembly of
Nck2-dependent pY-proteins containing molecular
complexes and downregulation of cell surface adhesion
proteins.
Nck2 promotes primary melanoma-derived tumor growth
in vivo
To establish the biological relevance of our findings,
we examined whether overexpression of Nck2 in
human primary melanoma cells confers some tumori-
genic advantage in a xenograft mouse model. To test
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Figure 5 Effect of Nck2 on human primary melanoma cell migration. Human primary melanoma cell migration was evaluated using wound
healing assays on WM278 cells overexpressing GFP (C2) or increasing levels of GFP-Nck2 (N15 < N7 < N14). Pictures from the same area were
taken at time 0 and 8 hours after the wound. Magnification: 10X and white bar = 200 μm. Quantification of migration is expressed as
percentage of closed wound ± SD. * p < 0.001 vs C2 using Student’s t-test.
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Figure 6 Effect of Nck2 on human primary melanoma cell derived spheroid in type 1 collagen and invasion. (A) Spheroids of human
primary WM278 melanoma cells overexpressing GFP (C2) or GFP-Nck2 (N14) and human metastatic WM1617 melanoma cells embedded in 3D
type I collagen gel were analyzed for morphology and invading cells. Pictures (10X) were taken at time 0 and after 48 hours of culture. White
bars = 200 μmo r5 0μm for zoomed pictures. (B) Invasion of human primary WM278 melanoma cells overexpressing GFP (C2) or GFP-Nck2
(N14) was evaluated using Matrigel™ transwell assays. Results are expressed as the mean of invaded cells ± SD from one experiment performed
in triplicate. * p < 0.01 vs C2 using Student’s t-test. Similar results were observed in three independent experiments.
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Figure 8 Effect of Nck2 on phosphotyrosine proteins in human melanoma cells. (A) Tyrosine phosporylated proteins in total cell lysates (30
μg protein) prepared from human primary (WM278) or metastatic (WM1617, WM164) melanoma cells, as well as from WM278 cells
overexpressing GFP (C2) or GFP-Nck2 (N7, N14), treated with or without pervanadate (Na3VO4 at 100 μM, 15 min at 37°C), were evaluated by
western blot using specific p-Tyr antibody. b-tubulin was probed as loading control. (B) Tyrosine phosporylated proteins coimmunoprecipitated
with Nck2, pan-Nck or normal rabbit IgGs from human primary WM278 and metastatic WM1617 melanoma cell lysates were revealed by western
blot using specific p-Tyr antibody. Arrow heads show proteins specific to or increased in Nck2 and pan-Nck IPs. Results shown are typical of 3-5
independent experiments.
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Page 13 of 19this, WM278 human primary melanoma cells overex-
pressing GFP-Nck2 at low (N7) or high (N14) levels,
along with parental WM278 cells, WM278 cells over-
expressing GFP (C2) and WM1617 human metastatic
melanoma cells were injected subcutaneously into CD-
1 Nude mice. Two out of 5 mice injected with
WM278 human primary melanoma cells overexpres-
sing high levels of GFP-Nck2 (N14) developed tumor
at the site of injection between 13-16 weeks post
injection (Figure 10A). At the same time, 1 out of 5
mice that received either parental WM278 cells,
WM278 melanoma cells overexpressing GFP (C2) or
overexpressing low levels of GFP-Nck2 (N7) presented
a subcutaneous tumor at the site of injection. In con-
trast, all mice injected with the metastatic WM1617
cells developed tumors at the site of injection 2-7
weeks post-injection (Figure 10A). As expected,
tumors derived from metastatic WM1617 cells grew
rapidly and reached maximal volume allowed between
5-11 weeks post-injection. Altogether, these observa-
tions suggest that increased expression of Nck2 in
human melanoma cells is not sufficient to promote
the appearance of subcutaneous tumor derived from
melanoma. However, melanoma-derived tumor growth
rate in mice injected with WM278 cells overexpressing
GFP-Nck2 (N7 and N14) was greatly enhanced com-
pared with tumor found in mice injected with WM278
cells parental or overexpressing GFP (C2) (Figure
10B), suggesting that increased expression level of
Nck2 promotes primary melanoma-derived tumor
growth rate. Subcutaneous tumors derived from
WM278 cells overexpressing GFP-Nck2 (N7 and N14)
could not be further monitored than few weeks after
their occurrence due to the appearance of important
spontaneous tumor necrosis core that required mice
to be euthanized. Nevertheless, in line with our in
vitro studies (Figure 3B), these results strongly support
a role for Nck2 in melanoma-derived tumor growth
rate in vivo.
Nck2 expression is upregulated in invasive colon and
breast cancer cell lines
To find out whether increased expression of Nck2 dur-
ing cancer progression is observed in other cancer types
than in melanoma skin cancer, we assessed Nck iso-
forms protein levels in murine colon (CT) and human
breast cancer cell lines at different stages of progression
(Figure 11). The CT represent mouse tumorigenic colo-
nic carcinoma cell lines established in culture from
three transplantable murine tumors of colonic origin at
different stages of progression [37]. Based on growth
rate and metastatic spreading, CT26 is the most aggres-
sive, while CT51 is intermediary and CT36 is the least
and rarely metastasizes. Using these cells lines, we
observed that Nck1 protein levels are increased in the
metastatic CT26 and CT51, while just barely detected in
CT36. However, when Nck1 expression levels were nor-
malized according to actin, these variations were not
statistically significant. In contrast, Nck2 that was below
detection level in CT36 and CT51, was distinctly
detected in CT26, revealing increased expression of
Nck2 in aggressive metastatic colon cancer cells. To
determine whether expression of Nck isoforms vary dur-
ing breast cancer progression, we selected few of the
widely used human breast cancer cell lines (MCF-7, T-
47D and MDA-MB-231) and an immortalized normal
human breast epithelial cell line (MCF10A). MCF-7, T-
47D and MDA-MB-231 are invasive ductal carcinoma of
similar origin with metastatic properties [38]. Indepen-
dently of estrogen receptor expression (ER+: MCF-7 and
T-47D; ER-: MDA-MB-231) or epithelial/mesenchymal
phenotype (epithelial-like low invasion: MCF-7 and T-
47D; mesenchymal-like high invasion: MDA-MB-231),
Nck1 protein levels in breast cancer cells were not con-
sistent with the cancer stage. Considering actin as load-
ing control, Nck1 protein levels were significantly
increased in T-47D cells, decreased in MDA-MB-231
cells and not change in MCF7 cells compared to MCF-
10A cells, excluding a potential correlation between
Nck1 expression levels and breast cancer progression. In
contrast, Nck2 was only detected in the most aggressive
MDA-MB-231 cells, which are mesenchymal-like ER+
breast cancer cells with strong migratory and metastatic
abilities [38,39]. Together these results provide the first
evidence that the expression of Nck2 is increased in
metastatic cancer cells of various origins and argue for a
role of Nck2 in cancer progression.
Discussion
Nck1 and Nck2 SH2-SH3 domain-containing proteins
have been reported to be differently expressed in
C2 N14 N7 WM278 WM1617
Integrin ȕ1
Integrin ȕ3
E-Cadherin
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Tubulin
Figure 9 Effect of Nck2 on cadherins and integrins expression
in human melanoma cells. Total cell lysates (50 μg protein)
prepared human primary (WM278) or metastatic (WM1617)
melanoma cells, as well as WM278 cells overexpressing GFP (C2) or
GFP-Nck2 (N7, N14) were probed for cadherins and integrins using
specific antibodies. b-tubulin used as loading control.
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Page 14 of 19numerous mouse tissues [8,15]. In agreement with the
ability of both Nck to collaborate with strong oncogenes
to transform cells [6], Nck1 and Nck2 genes were found
upregulated in several human cancer cell lines, including
melanoma (https://www.oncomine.org/). However, Nck
proteins expression levels in cancer tissues and possible
mechanism(s) by which these adaptors contribute to
cancer development have been poorly investigated to
date. In this study, we provide evidence that Nck2 plays
a role in promoting proliferation, migration and invasion
of human melanoma cells in vitro and growth of
melanoma-derived tumors in vivo, while its expression
is upregulated in metastatic cancer cells, including
colon, breast and melanoma.
Our investigation revealing that Nck2 overexpression
in human primary melanoma cells induces metastatic
characteristics point towards Nck2 sufficiency to pro-
mote metastasis phenotype. In this study, we did not
address whether Nck2 is necessary for melanoma metas-
tasis. However, we provided some insights suggesting
that Nck2 could play such function. In fact, we found
higher levels of Nck2 expression in metastatic compared
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Figure 10 Effect of Nck2 on human primary melanoma-derived tumor growth in vivo. CD-1 Nude mice of 6-week-old were injected
subcutaneously with human parental WM278 primary melanoma cells, WM278 cells overexpressing either GFP or GFP-Nck2, or human WM1617
metastatic melanoma cells (5 × 10
6) into the right flank. (A) The mice were monitored for tumor development. (B). Tumor volume progression
assessed with calipers every week in indicated mice. Tumors with volume bigger than 50 mm
3 (dashed line) were considered during the course
of the study.
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Page 15 of 19to non metastatic cell lines in three different types of
cancer. In addition, we demonstrate that depletion of
Nck2 in metastatic melanoma reduces cell proliferation.
This does not exclude that other yet identified players
could be required to fully promote metastasis in mela-
noma overexpressing Nck2. None the less, our findings
clearly demonstrate that overexpression of Nck2 in
human primary melanoma correlates with upregulation
of the total phospho-tyrosine proteins content, assembly
of novel Nck2-dependent pY-protein complexes and
downregulation of E- and N-cadherins, and b-1 and -3
integrins. E-cadherin, found at adherens junctions, is the
principal effector of cell-cell adhesion [40]. Loss of E-
cadherin expression in cancer cells weakens cell-cell
adhesion and is associated with cancer progression,
invasion and metastasis [41-43]. At the present time,
there is no evidence for a direct link between E-cadherin
and Nck2. Further investigation is required to elucidate
the molecular events responsible for E-cadherin downre-
gulation associated with overexpression of Nck2 in
human primary melanoma cells and whether downregu-
lation of Nck2 in metastatic human melanoma cells
would restore E-cadherin expression remains to be
determined. On the other hand, the degree of cancer
cells cohesion in primary tumor also depends on the
strength of cell-ECM contacts mediated by integrins
[44]. Alteration in integrins expression has been also
implicated in cancer progression, invasion and metasta-
sis [45,46]. Integrins signaling associated with regulation
of the actin cytoskeleton leading to adhesive attachment
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Figure 11 Expression of Nck1 and Nck2 in colon and breast cancer cells. Lysates (50 μg protein) from murine colonic carcinoma cells (A)
and human breast cancer cells (B) were subjected to western blot analysis using anti-Nck specific antibodies (Additional file 1). CT36: rarely
metastatic; CT51: intermediary; CT26: highly metastatic. MCF-10A: Normal human breast epithelial; MCF7, T47D, MDA-MB-231: invasive metastatic
ductal carcinoma. For both cancer cell types, b-actin was probed as loading control.
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Page 16 of 19involves the activation of the focal adhesion kinase
(FAK) and the integrin-like kinase (ILK) (reviewed in
[47]). Interestingly, Nck2 has been shown to affect cell
motility through its direct interaction with FAK [48].
Moreover, increasing evidence support a close relation-
ship between integrins and growth factor receptor tyro-
sine kinases to activate signaling pathways that promote
proliferation and metastatic activity (reviewed in [49]).
Nck2 has been reported to function as a molecular link
connecting integrins and growth factor receptor tyrosine
kinases signaling pathways. In fact, Nck2 associates with
numerous receptor tyrosine kinases [17,50-54] through
its SH2 domain and using its third SH3 domain, it
binds to a LIM domain in PINCH (Particularly Interest-
ing Cys-His-rich Protein) [55]. PINCH, a binding pro-
tein for ILK, plays an important role in mediating
integrins-induced cell-ECM interaction by directing ILK
to focal adhesions [56]. It is recognized that the ILK-
PINCH complex participates to signaling pathways regu-
lating fundamental cellular processes (reviewed in [57],
including cell shape and migration [58]. A crucial role
for Nck in regulating these processes was particularly
illustrated by the findings showing that fibroblasts
derived from Nck double knockout mice embryos dis-
play major defects in cell attachment, cell motility and
actin remodeling [8]. Therefore, increased expression of
Nck2 in human primary melanoma cells may elicit pro-
tein interactions that re-wire signaling pathways in a
fashion that alters focal adhesions and promotes cell
motility by interacting with FAK and PINCH. Alterna-
tively, increased expression of Nck2 could passively
destroy proper stoichiometry of molecular complexes
and in this manner, indirectly contributes to cancer pro-
gression by altering signaling pathways regulating the
actin cytoskeleton network supporting cell migration.
Nck proteins are known to couple activated receptor
tyrosine kinases, as well as non receptor tyrosine kinases,
to effectors involved in signaling pathways regulating
p r o l i f e r a t i o na n da c t i nc y t o s k e l e t o nd y n a m i c s
[7,14,59-61]. Non-receptor protein kinases of the Src and
Abl families are often overexpressed or aberrantly acti-
vated in a wide variety of human cancers and their roles
in cancer progression, including proliferation, survival,
motility, invasiveness, metastasis and angiogenesis, is sig-
nificant. Of note, Nck directly binds to and promotes Abl
activation and signaling [62,63], and associates with p60
v-
src in vitro [16]. c-Src has been recently reported to be
overexpressed in human metastatic melanoma tumors
[64]. Interestingly, Src-dependent phosphorylation of
Tks5 and cortactin recruits Nck to invadopodia, where it
regulates actin assembly and ECM degradation [65-67].
Invadopodia, exclusive invasive cancer cell membrane
actin-based protrusions enriched in signaling and proteo-
lytic activities, are used by invasive cancer cells to
degrade the ECM and invade surrounding tissues
[68-71]. It is then possible that upregulation of tyrosine
phosphorylated proteins and downregulation of cadher-
ins and integrins in human primary melanoma cells that
overexpress Nck2 may endow melanoma cells with
altered adhesive properties and spatial relationships that
favor uncontrolled proliferation, migration and invasion.
Nck1 and Nck2 proteins are highly identical, but
despite high homology, redundant functions and com-
mon binding partners, increasing evidence suggest speci-
fic roles and protein interactions [7,9-12,14], as well as
specific tissue expression patterns for Nck proteins
[8,15]. In this study, the effect of Nck1 overexpression
on melanoma phenotype was not addressed. However,
our results demonstrate that increased endogenous
expression of Nck2 in human metastatic melanoma cells
relative to primary melanoma cells and melanocytes
results from increased Nck2 transcription, suggesting
that Nck1 and Nck2 promoters are under different regu-
latory controls.
Conclusions
In conclusion, in this study we provide evidence for a
role of the adaptor protein Nck2 in melanoma prolifera-
tion, migration and invasion in vitro and melanoma-
derived tumor growth in vivo. Collectively, our data sup-
port Nck2 as a cornerstone governing the aspects that
promote melanoma progression. Given other common
metastatic cancer cell lines also overexpress Nck2, a
general paradigm could make Nck2 a potential molecu-
lar marker of cancer progression and a novel target for
anti-cancer drug therapy.
Additional material
Additional file 1: Nck isoforms specific antibodies. Equivalent amount
of total cell lysates (25 μg protein) of 293HEK cells overexpressing similar
levels of human HA-Nck1 or HA-Nck2 proteins were probed by western
blots using indicated antibodies.
Additional file 2: Nck1 and CrkII expression in human melanoma
cell lines at different stages of cancer progression. Equivalent
amount of total cell lysate proteins (30 ug) from various human
melanoma cell lines were subjected to western blot analysis using anti-
CrkII and anti-Nck1 specific antibodies. b-tubulin was probed as loading
control.
Additional file 3: Effect of Nck2 on human primary melanoma cell
migration. Melanoma migration was evaluated 8 h post wounding in
wound healing assays using WM278 human primary melanoma cells 24
h following infection with retrovirus transducing or not HA-Nck2.
Quantification of melanoma migration is expressed as mean of wound
closed in mm ± SEM. * p < 0.05 compared to control using Student’s t-
test.
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